Corcept Therapeutics Inc expected to post earnings of 14 cents a share - Earnings Preview

Corcept Therapeutics Incorporated

02/05/2025 21:12

Corcept Therapeutics Inc CORT.OQ CORT.O is expected to show a rise in quarterly revenue when it reports  results on May 5 for the period ending March 31 2025

The Redwood City California-based  company is expected to report a 21.2% increase in revenue to $177.936 million from $146.81 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Corcept Therapeutics Inc is for earnings of 14 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 0.3% in the last three months. ​

Wall Street's median 12-month price target for Corcept Therapeutics Inc is $146.00​, above​ its last closing price of $71.48. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.44
0.43
0.26
Missed
-39
Sep. 30 2024
0.29
0.28
0.41
Beat
45.4
Jun. 30 2024
0.24
0.23
0.32
Beat
39.1​
Mar. 31 2024
0.23
0.22
0.25
Beat
13.6
​​Dec. 31 2023
0.27
0.26
0.28
Beat
8.5
Sep. 30 2023
0.23
0.22
0.28
Beat
28.2​
Jun. 30 2023
0.15
0.15
0.25
Beat
66.7
Mar. 31 2023
0.19
0.19
0.14
Missed
-27.6

This summary was machine generated May 2 at 20:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)